Issue :

Saudi FDA issued a recall of the mentioned batches of Glyxambi 25mg/5mg film-coated tablets due to a printing error of (empagliflozin) concentration on the outside packaging. Boehringer Ingelheim Pharma is voluntarily recalling the affected batches on the warehouse level only.

Recommendations :

For healthcare professionals, this is a notification about the voluntary recall no action is required as the product quality is not impacted.